Form 4: CFO Dina Masi Granted 140,000 Stock Options in INBP

Integrated Biopharma's CFO, Dina Masi, received a grant of 140,000 stock options with a $0.31 exercise price, vesting over three years.

Summary

• Dina Masi, Chief Financial Officer of Integrated Biopharma Inc. (INBP), was granted 140,000 stock options.
• The transaction date for this acquisition of derivative securities was December 9, 2025.
• Each option has an exercise price of $0.31.
• The options will vest in three equal annual installments, with the first installment vesting on December 9, 2026.
• The options have an expiration date of December 9, 2035.
• Following this transaction, Dina Masi beneficially owns 140,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (stock option grant) which is generally neutral but can be seen as slightly positive due to incentive alignment. It does not contain significant new financial or operational information to warrant a strong positive or negative sentiment.

Positives

• The grant of stock options aligns the Chief Financial Officer's incentives with the long-term performance and shareholder value of Integrated Biopharma Inc.
• The options provide a potential future value opportunity for the CFO, contingent on the company's stock price appreciation above the exercise price.

Negatives

• The future exercise of these options could lead to a minor dilutive effect on existing shareholders, although this is a standard aspect of equity compensation plans.

Risks

• The value of the stock options is dependent on the future market price of Integrated Biopharma Inc. common stock exceeding the $0.31 exercise price; if the stock price remains below this, the options may not be exercised.
• The options vest over three years, meaning the CFO's ability to fully realize the benefit is tied to continued employment and company performance over that period.

Future Outlook

The stock options are structured to vest in three equal annual installments, with the first vesting on December 9, 2026, indicating a long-term incentive structure for the Chief Financial Officer. The options have a ten-year expiration period, allowing for potential future value realization.

Industry Context

This executive stock option grant is a common practice in the biopharma industry and broader corporate landscape, used to attract, retain, and incentivize key management personnel by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a standard component of executive compensation packages across various industries, including biopharma, aiming to incentivize long-term performance.
• The vesting schedule of three equal annual installments is a typical structure for equity awards, promoting executive retention and sustained focus on company growth.
• An exercise price of $0.31, if at or above the market price on the grant date, is standard for incentive stock options, ensuring that the executive benefits only if the company's stock price appreciates.

Management Changes

Related Party Transactions

• The stock option grant to Dina Masi, a Chief Financial Officer, constitutes a transaction between the company and an insider, which is a common form of executive compensation.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised in the future, but also benefits from increased alignment of management's interests with long-term shareholder value.
• Employees: No direct impact on general employees mentioned, but reflects the company's executive compensation strategy.
• Management (Dina Masi): Receives a significant equity incentive, tying personal financial success to the company's stock performance.

Next Steps

• The stock options will vest in three equal annual installments, with the first installment occurring on December 9, 2026.
• The Chief Financial Officer may choose to exercise the vested options at any point before their expiration date of December 9, 2035, assuming the stock price is favorable.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) and does not provide new fundamental information about the company's financial performance, strategic direction, or operational health. As such, it does not warrant a change in investment recommendation based solely on this disclosure. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Integrated Biopharma, INBP, Stock Options, CFO, Dina Masi, Executive Compensation, Insider Transaction, Equity Grant